Introduction
The American Head and Neck Society met May 30-31, 2009 in Phoenix, Arizona for its 2009 Annual Meeting. Many specialists gathered to explore both clinical and research level head and neck cancer scientific findings. This newsletter provides highlights from the annual meeting and offers medical oncologists, surgical oncologists, radiation oncologists, oncology specialty pharmacists, and other allied healthcare professionals caring for patients with head and neck cancers with leading-edge information on head and neck cancer treatment.
Editors
Robert Haddad, MD, bio | Barbara A. Murphy, MD, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours. Release date: June 22, 2009 | Expiration date: June 23, 2010
Statement of Need
Advances in head and neck cancer (HNC) have resulted from decades of well-designed clinical trials and new insights into the biology as well as shifts in epidemiology, increasing development of and access to new agents, and rapid advances in diagnostic and therapeutic technologies. The management of HNC in recent years has involved increasingly complex, combined-modality treatment approaches. Advances in treatment strategies have affected all the approaches used in HNC: radiation therapy, chemotherapy, targeted agents, and surgery and supports a best practices model of multidisciplinary team involvement. Numerous ongoing trials are assessing the benefits of these and other novel agents, and as such, it is imperative that physicians and allied healthcare professionals (including nurses, nutritionists, pharmacists, and speech/swallow therapists) treating HNC patients be informed of the results of these trials to facilitate optimal management of HNC patients. This newsletter will highlight areas of new knowledge from the 2009 annual meeting, the world’s preeminent venue for presentation of new data in oncology. These findings will be placed in perspective with the most recent standards of care by editors chosen for their expertise and leadership in the field.
Target Audience
The target audience for the program includes medical oncologists, surgical oncologists, radiation oncologists, oncology specialty pharmacists, and other allied healthcare professionals caring for patients with head and neck cancers.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Describe the design and results of studies on treatment of head and neck cancer presented at the American Head and Neck Society Annual Meeting
- Interpret study results in light of current standard of care of head and neck cancer
- Outline recent information on risk factors for, prevention of, and management of serious treatment-related side effects in head and neck cancer
- Incorporate individual patient parameters and toxicity considerations in selection of treatment for head and neck cancer
_____________________________________________________________________________________________________________________________________ |
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council
for Continuing Medical Education to provide continuing medical education
for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim
credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
|
 |
| Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of Activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UPN 199-000-09-038-H01-P).
|
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity.
During the period June 22, 2009 through June 23, 2010, participants must
1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test and activity evaluation form.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Educational Concepts Group, LLC (ECG) does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE | Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net |
|
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
Barbara A. Murphy, MD
Grants/Research Support
Bristol-Myers Squibb Company
Consultant Fees, Honorarium
EUSA Pharma
Robert Haddad, MD
No financial relationships to disclose
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from sanofi-aventis Group.
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
|
|
